<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">IJMM</journal-id>
<journal-title-group>
<journal-title>International Journal of Molecular Medicine</journal-title></journal-title-group>
<issn pub-type="ppub">1107-3756</issn>
<issn pub-type="epub">1791-244X</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name></publisher></journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/ijmm.2013.1500</article-id>
<article-id pub-id-type="publisher-id">ijmm-32-05-1077</article-id>
<article-categories>
<subj-group>
<subject>Articles</subject></subj-group></article-categories>
<title-group>
<article-title>Saponin B, a novel cytostatic compound purified from <italic>Anemone taipaiensis</italic>, induces apoptosis in a human glioblastoma cell line</article-title></title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>WANG</surname><given-names>YUANGANG</given-names></name><xref rid="af1-ijmm-32-05-1077" ref-type="aff">1</xref><xref rid="fn1-ijmm-32-05-1077" ref-type="author-notes">&#x0002A;</xref></contrib>
<contrib contrib-type="author">
<name><surname>TANG</surname><given-names>HAIFENG</given-names></name><xref rid="af2-ijmm-32-05-1077" ref-type="aff">2</xref><xref rid="fn1-ijmm-32-05-1077" ref-type="author-notes">&#x0002A;</xref></contrib>
<contrib contrib-type="author">
<name><surname>ZHANG</surname><given-names>YUN</given-names></name><xref rid="af3-ijmm-32-05-1077" ref-type="aff">3</xref><xref rid="fn1-ijmm-32-05-1077" ref-type="author-notes">&#x0002A;</xref></contrib>
<contrib contrib-type="author">
<name><surname>LI</surname><given-names>JUAN</given-names></name><xref rid="af1-ijmm-32-05-1077" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author">
<name><surname>LI</surname><given-names>BO</given-names></name><xref rid="af1-ijmm-32-05-1077" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author">
<name><surname>GAO</surname><given-names>ZHENHUI</given-names></name><xref rid="af1-ijmm-32-05-1077" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author">
<name><surname>WANG</surname><given-names>XIAOYANG</given-names></name><xref rid="af2-ijmm-32-05-1077" ref-type="aff">2</xref></contrib>
<contrib contrib-type="author">
<name><surname>CHENG</surname><given-names>GUANG</given-names></name><xref rid="af1-ijmm-32-05-1077" ref-type="aff">1</xref><xref ref-type="corresp" rid="c1-ijmm-32-05-1077"/></contrib>
<contrib contrib-type="author">
<name><surname>FEI</surname><given-names>ZHOU</given-names></name><xref rid="af1-ijmm-32-05-1077" ref-type="aff">1</xref><xref ref-type="corresp" rid="c1-ijmm-32-05-1077"/></contrib></contrib-group>
<aff id="af1-ijmm-32-05-1077">
<label>1</label>Department of Neurosurgery, Xijing Institute of Clinical Neuroscience, Xijing Hospital, Fourth Military Medical University, Xi&#x02019;an, Shannxi, P.R. China</aff>
<aff id="af2-ijmm-32-05-1077">
<label>2</label>Department of Pharmacology, Xijing Hospital, Fourth Military Medical University, Xi&#x02019;an, Shannxi, P.R. China</aff>
<aff id="af3-ijmm-32-05-1077">
<label>3</label>Department of Immunology, Fourth Military Medical University, Xi&#x02019;an, Shannxi, P.R. China</aff>
<author-notes>
<corresp id="c1-ijmm-32-05-1077">Correspondence to: Professor Guang Cheng or Professor Zhou Fei, Department of Neurosurgery, Xijing Institute of Clinical Neuroscience, Xijing Hosipital, Fourth Military Medical University, No. 127 Changle Western Road, Xi&#x02019;an, Shannxi 710032, P.R. China, E-mail: <email>chg16801@163.com</email>, E-mail: <email>feizhou@fmmu.edu.cn</email></corresp><fn id="fn1-ijmm-32-05-1077">
<label>&#x0002A;</label>
<p>Contributed equally</p></fn></author-notes>
<pub-date pub-type="ppub">
<month>11</month>
<year>2013</year></pub-date>
<pub-date pub-type="epub">
<day>18</day>
<month>09</month>
<year>2013</year></pub-date>
<volume>32</volume>
<issue>5</issue>
<fpage>1077</fpage>
<lpage>1084</lpage>
<history>
<date date-type="received">
<day>06</day>
<month>06</month>
<year>2013</year></date>
<date date-type="accepted">
<day>04</day>
<month>09</month>
<year>2013</year></date></history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2013, Spandidos Publications</copyright-statement>
<copyright-year>2013</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0">
<license-p>This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.</license-p></license></permissions>
<abstract>
<p>Glioblastoma multiforme (GBM) is one of the most common malignant brain tumors. Saponin B, a novel compound isolated from the medicinal plant, <italic>Anemone taipaiensis</italic>, has been found to have a strong time- and dose-dependent cytostatic effect on human glioma cells and to suppress the growth of U87MG GBM cells. In this study, we investigated whether saponin B induces the apoptosis of glioblastoma cells and examined the underlying mechanism(s) of action of saponin B. Saponin B significantly suppressed U87MG cell proliferation. Flow cytometric analysis of DNA in the U87MG cells confirmed that saponin B blocked the cell cycle at the S phase. Furthermore, treatment of the U87MG cells with saponin B induced chromatin condensation and led to the formation of apoptotic bodies, as observed under a fluorescence microscope, and Annexin V/PI assay further suggested that phosphatidylserine (PS) externalization was apparent at higher drug concentrations. Treatment with saponin B activated the receptor-mediated pathway of apoptosis, as western blot analysis revealed the activation of Fas-l. Saponin B increased the Bax and caspase-3 ratio and decreased the protein expression of Bcl-2. The results from the present study demonstrate that the novel compound, saponin B, effectively induces the apoptosis of GBM cells and inhibits glioma cell growth and survival. Therefore, saponin B may be a potential candidate for the development of novel cancer therapeutics with antitumor activity against gliomas.</p></abstract>
<kwd-group>
<kwd>apoptosis</kwd>
<kwd><italic>Anemone taipaiensis</italic></kwd>
<kwd>cell viability</kwd>
<kwd>human glioblastoma</kwd>
<kwd>U87MG cells</kwd>
<kwd>anticancer drug</kwd></kwd-group></article-meta></front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Glioblastoma is one of the most malignant human tumors (<xref ref-type="bibr" rid="b1-ijmm-32-05-1077">1</xref>), and despite aggressive surgical resection and radiotherapy, the median survival for patients with glioma does not normally exceed one year (<xref ref-type="bibr" rid="b2-ijmm-32-05-1077">2</xref>&#x02013;<xref ref-type="bibr" rid="b4-ijmm-32-05-1077">4</xref>). Glioblastoma multiforme (GBM) is able to avoid immunosurveillance and the tumor cells proliferate extensively with strikingly high rates due to its intrinsic properties. The success of chemotherapy in patients with GBM is hampered by the issue of drug resistance, and the need for the discovery of more effective agents and therapeutic regimens to treat GBM is becoming increasingly urgent (<xref ref-type="bibr" rid="b5-ijmm-32-05-1077">5</xref>). Numerous plant-derived compounds, such as betulinic (<xref ref-type="bibr" rid="b6-ijmm-32-05-1077">6</xref>) and asiatic acids (<xref ref-type="bibr" rid="b7-ijmm-32-05-1077">7</xref>) have been reported to be potential anti-glioma agents, although most of these compounds are no longer considered as possible treatments for human glioma. This is due either to their modification in the liver or to their inability to pass through the blood-brain barrier.</p>
<p>Traditional Chinese medicinal herbs are widely known to be effective in the treatment of a number of diseases. For example, arteannuin and dihydroartemisinin tablets purified from sweet wormwood have been used to cure malaria. Examples of plant-based therapeutic anticancer drugs include camptothecin from <italic>Camptotheca acuminata</italic>, etoposide from <italic>Podophyllum peltatum</italic>, vincristine from <italic>Catharanthus roseus</italic> and paclitaxel from <italic>Taxus</italic> (yew) (<xref ref-type="bibr" rid="b8-ijmm-32-05-1077">8</xref>,<xref ref-type="bibr" rid="b9-ijmm-32-05-1077">9</xref>).</p>
<p>Saponin B was first isolated from <italic>Anemone taipaiensis</italic>, a ferine plant of the Qinling mountains of southern Shaanxi province, China, that is distributed in the hill country of the fertile slopes or rocky grasslands at altitudes between 2,900 and 3,700 m. Wang <italic>et al</italic> isolated eight saponins from <italic>Anemone taipaiensis</italic> (<xref ref-type="bibr" rid="b10-ijmm-32-05-1077">10</xref>). In this study, we first investigated the effects of saponin B on the human U87MG GBM cell line, as an <italic>in vitro</italic> model to explore the effects of saponin B on GBM cell growth and apoptosis. Apoptosis is a physiological, energy-requiring process that is characterized by the formation of apoptotic bodies inside cells and seems to be genetically programmed (<xref ref-type="bibr" rid="b11-ijmm-32-05-1077">11</xref>). It is widely accepted that apoptosis is preferred to necrosis as a mechanism of tumor cell killing, since apoptosis does not promote inflammatory processes (<xref ref-type="bibr" rid="b12-ijmm-32-05-1077">12</xref>,<xref ref-type="bibr" rid="b13-ijmm-32-05-1077">13</xref>). The demonstration of apoptotic capacity would therefore make this substance of interest as a potential anticancer reagent.</p></sec>
<sec sec-type="methods">
<title>Materials and methods</title>
<sec>
<title>Cell culture</title>
<p>The following three cell lines were obtained from the American Type Culture Collection (ATCC): ECV304 (human umbilical vein endothelial cells), U87MG and U251MG (GBM cells). Human GBM cells used in this study were grown as a monolayer culture in Dulbecco&#x02019;s modified Eagle&#x02019;s medium (DMEM; Gibco-BRL, Carlsbad, CA, USA) supplemented with 10&#x00025; fetal bovine serum (Gibco-BRL) and antibiotics in a humidified atmosphere containing 5&#x00025; CO<sub>2</sub> at 37&#x000BA;C.</p></sec>
<sec>
<title>Drug sample</title>
<p>Saponin B was obtained from the Department of Pharmacology of Xijing Hospital, Fourth Military Medical University, Xi&#x02019;an, China and established as 3&#x003B2;-O-&#x0007B;&#x003B2;-D-xylopyranosyl-(1&#x02192;3)-&#x003B1;-L-rhamnopyranosyl-(1&#x02192;2)-&#x0005B;&#x003B2;-D-gluco- pyranosyl-(1&#x02192;4)&#x0005D;-&#x003B1;-L-arabinopyranosyl&#x0007D; oleanolic acid 28-O-&#x0007B;&#x003B1;-L-rhamnopyranosyl-(1&#x02192;4)-&#x003B2;-D-glucopyranosyl-(1&#x02192;6)-&#x003B2;-D-glucopyranoside&#x0007D;; the molecular formula was C<sub>70</sub>H<sub>114</sub>O<sub>34</sub> (molecular weight, 1,498). The molecular structure of saponin B is shown in <xref rid="f1-ijmm-32-05-1077" ref-type="fig">Fig. 1A</xref>. The purity of the sample was assessed by high-performance liquid chromatography (HPLC) as more than 95&#x00025; (<xref rid="f1-ijmm-32-05-1077" ref-type="fig">Fig. 1B</xref>). The reagent was placed in dimethyl sulfoxide (DMSO) and shaken until the powder dissolved, then diluted with the culture solution (DMEM). The stock solutions were stored at 4&#x000BA;C and the volume of DMSO was maintained at &lt;0.5&#x00025; so as not to affect cell growth. The final concentration of the stock solution was confirmed at 500 &#x003BC;g/ml.</p></sec>
<sec>
<title>3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay</title>
<p>Following the treatments, cell viability was examined by MTT assay. The U87MG and U251MG cells were seeded at a density of 3&#x000D7;10<sup>4</sup> cells/well into 96-well plates prior to drug treatment. Saponin B was added to the medium and the cells were continuously treated for 72 h at different concentrations (1.3&#x02013;42.7 &#x003BC;mol/l), and then MTT assay was performed as previously described by Mickisch <italic>et al</italic> (<xref ref-type="bibr" rid="b14-ijmm-32-05-1077">14</xref>). The controls cells were incubated in control medium containing 0.1&#x00025; DMSO.</p></sec>
<sec>
<title>Cell cycle analysis</title>
<p>In order to analyze the effect of saponin B on the cell cycle distribution of U87MG glioblastoma cells, flow cytometry was used to elucidate the mechanisms behind the inhibition of proliferation. The U87MG cells were trypsinized, counted, centrifuged and fixed in ethanol at certain time points after the treatment. The cells were then washed twice in phosphate-buffered saline (PBS) and centrifuged. The pellets were resuspended in a solution of ribonuclease (0.02 mg/ml, Sigma, St. Louis, MO, USA) and propidium iodide (PI; 0.02 mg/ml, Sigma), and incubated at 4&#x000BA;C for 30 min. The fluorescence of approximately 10,000&#x02013;20,000 stained cells was measured. The results were expressed as a plot of fluorescence intensity vs. cell number as previously described (<xref ref-type="bibr" rid="b15-ijmm-32-05-1077">15</xref>).</p></sec>
<sec>
<title>Cellular and nuclear morphology</title>
<p>We determined the residual cell viability and number of apoptotic U87MG glioblastoma cells following treatment with saponin B at various concentrations &#x0005B;inhibitory concentration (IC)<sub>25</sub>, IC<sub>50</sub> and IC<sub>75</sub>&#x0005D; for 8 and 24 h. Apoptosis was analyzed after staining the cells with Hoechst 33342 (Sigma) at a final concentration of 1.5 &#x003BC;M for 10 min and cell morphology was determined using a fluorescence microscope (Zeiss Axiovert 200; Carl Zeiss, Oberkochen, Germany). The cells were analyzed at &#x000D7;40 magnification and documented using a charge-coupled device (CCD) camera (Zeiss Axiocam MR; Carl Zeiss). We determined the number of apoptotic cells based on characteristic morphological features. The percentage of apoptotic cells was calculated from three separate experiments (<xref ref-type="bibr" rid="b16-ijmm-32-05-1077">16</xref>,<xref ref-type="bibr" rid="b17-ijmm-32-05-1077">17</xref>).</p></sec>
<sec>
<title>Annexin V/PI staining</title>
<p>Fluorophore-labeled Annexin V &#x0005B;a protein that exhibits nanomolar affinity for phosphatidylserine (PS)&#x0005D; binding to externalized PS has been extensively employed as a reliable marker of apoptosis. The appearance of PS on the extracellular cell membranes was therefore evaluated with Annexin V/PI staining (<xref ref-type="bibr" rid="b18-ijmm-32-05-1077">18</xref>). The U87MG glioblastoma cells (1&#x000D7;10<sup>6</sup>) treated as described above were washed twice in PBS, and then trypsinized with 0.13 g/l trypsin in PBS-EDTA (ethylenediaminetetraacetic acid). We then terminated the trypsin reaction with culture medium containing 10&#x00025; fetal bovine serum. The cells were collected, centrifuged (5 min, 800 &#x000D7; g, 4&#x000BA;C), washed twice in ice-cold PBS and resuspended in 1X binding buffer (10 mM HEPES/NaOH, pH 7.4, 140 mM NaCl, 2.5 mM CaCl<sub>2</sub>). Subsequently, 5 &#x003BC;l of Annexin V-FITC (fluorescein isothiocyanate; BD Pharmingen, San Jose, CA, USA) and 10 &#x003BC;l of PI (50 &#x003BC;g/ml) were added to the 100 &#x003BC;l of cell suspension and incubated for 15 min at room temperature in the dark. Finally, 400 &#x003BC;l of binding buffer were added to the samples, which were kept ice cold until they were analyzed on a FACSCalibur (Becton Dickinson, Franklin Lakes, NJ, USA) flow cytometer. Ten thousand cells were analyzed per sample: viable cells (FITC<sup>&#x02212;</sup>PI<sup>&#x02212;</sup>), apoptotic cells (FITC<sup>&#x0002B;</sup>/PI<sup>&#x02212;</sup> and FITC<sup>&#x0002B;</sup>/PI<sup>&#x0002B;</sup>) and necrotic cells (FITC<sup>&#x02212;</sup>/PI<sup>&#x0002B;</sup>) as previously described (<xref ref-type="bibr" rid="b19-ijmm-32-05-1077">19</xref>&#x02013;<xref ref-type="bibr" rid="b22-ijmm-32-05-1077">22</xref>).</p></sec>
<sec>
<title>Analysis of DNA fragmentation</title>
<p>After being treated with saponin B for the pre-determined periods of time, the cells were collected, washed and pelleted by centrifugation, and 200 &#x003BC;l binding/lysis buffer (20 ml nucleic acid binding, 6 M guanidine-HCL, 10 mM urea, 10 mM tris-HCL, 20&#x00025; Triton X-100, pH 4.4) were added to 2&#x000D7;10<sup>6</sup> cells in a volume of 200 &#x003BC;l and mixed immediately. The cells were then incubated for 10 min at 25&#x000BA;C, 100 &#x003BC;l isopropanol were added and the sample was vortexed. We combined a filter tube and a collection tube and pipetted the sample. In addition, the suspension was centrifuged for 1 min at 8,000 rpm in a standard tabletop centrifuge. We discarded the flow through and again combined the filter tube and the used collection tube. We added 500 &#x003BC;l washing buffer to the upper reservoir and centrifuged for 1 min at 8,000 rpm. We then discarded the flow through and again combined the filter tube and the used collection tube. We added 500 &#x003BC;l washing buffer to the upper reservoir and centrifuged for 1 min at 8,000 rpm, finally centrifuging for 10 sec at the maximum speed, 13,000 rpm, to remove the residual washing buffer. We discarded the collection tube and inserted the filter tube in a clean 1.5 ml cup or tube, then used 200 &#x003BC;l of pre-warmed (70&#x000BA;C) elution buffer. We added elution buffer to the filter tube and centrifuged for 1 min at 8,000 rpm. Finally, following the manufacturer&#x02019;s instructions, the samples were loaded on 1&#x00025; agarose gel, separated by electrophoresis (50 V, 1.5 h) and visualized by staining with ethidium bromide (Roche, Cat. no. 11835246001, Basel, Switzerland) as previously described (<xref ref-type="bibr" rid="b23-ijmm-32-05-1077">23</xref>).</p></sec>
<sec>
<title>Western blot analysis</title>
<p>The activation of caspases followed by their cleavage is well known to be an important phenomenon for the induction of apoptosis (<xref ref-type="bibr" rid="b24-ijmm-32-05-1077">24</xref>). The Bcl-2 family, including Bcl-2, Bcl-xL, Bax and Bad, regulates various steps of apoptosis. Bax and Bad promote programmed cell death, whereas Bcl-2 and Bcl-xL block cell death (<xref ref-type="bibr" rid="b25-ijmm-32-05-1077">25</xref>,<xref ref-type="bibr" rid="b26-ijmm-32-05-1077">26</xref>) and the involvement of the <italic>Bcl-2</italic> gene in apoptosis has been reported by several studies on anticancer drugs (<xref ref-type="bibr" rid="b27-ijmm-32-05-1077">27</xref>,<xref ref-type="bibr" rid="b28-ijmm-32-05-1077">28</xref>). To identify the molecular mechanisms involved in the enhanced apoptosis observed in the U87MG cells treated with saponin B, we performed immunoblot analysis to detect caspase activation using specific antibodies. The cells were treated with saponin B, incubated for 8 and 24 h, and then collected, lysed in lysis buffer &#x0005B;150 mM NaCl, 1&#x00025; NP-40, 0.5&#x00025; sodium deoxycholate, 0.1&#x00025; SDS, 50 mM Tris-HCl, pH 8.0, 10 mM EDTA and 1 mM phenylmethanesulfonylfluoride (PMSF); Sigma&#x0005D; for 30 min, and the cells were homogenized at 4&#x000BA;C. For each sample, 30 &#x003BC;g of protein were loaded onto a 12.5&#x00025; SDS-polyacrylamide gel, electrophoresed, and transferred onto a nitrocellulose membrane (0.22 &#x003BC;m, Schleicher &amp; Schuell Protran; Schleicher &amp; Schuell BioScience GmbH, Dassel, Germany). The membranes were blocked for 1 h at room temperature with a blocking buffer &#x0005B;Tris-buffered saline containing 0.1&#x00025; Tween-20 (w/v); Sigma&#x0005D; and 5&#x00025; non-fat milk (w/v). Primary antibodies (applied for 1 h at room temperature, or overnight at 4&#x000BA;C) were anti-Bcl-2 (rabbit monoclonal Ab-1, Oncogene Science, Cambridge, MA, USA), anti-Bax (rabbit polyclonal N-20, Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-caspase-3 (rabbit, purity &gt;95&#x00025;), anti-Fas-l (rabbit, purity &gt;95&#x00025;), anti-actin (goat monoclonal C-2, Santa Cruz Biotechnology). All antibodies were diluted 1:1000, except for anti-actin (1:300).</p></sec></sec>
<sec sec-type="results">
<title>Results</title>
<sec>
<title>Cytostatic effect</title>
<p>Saponin B at doses ranging from 1.67 to 13.35 &#x003BC;mol/l exerted a significant anti-proliferative effect on the human glioblastoma cell line, as shown by time course analysis, and also exerted a strong dose-dependent cytostatic effect on human glioma cells. For the U87MG cells, the IC<sub>25</sub>, IC<sub>50</sub> and IC<sub>75</sub> of saponin B at 72 h were found to be IC<sub>25</sub>, 5.2 &#x003BC;mol/l; IC<sub>50</sub>, 6.7 &#x003BC;mol/l; and IC<sub>75</sub>, 8.7 &#x003BC;mol/l. For the U251MG cells, these concentrations were IC<sub>25</sub>, 6.2 &#x003BC;mol/l; IC<sub>50</sub>, 7.9 &#x003BC;mol/l; and IC<sub>75</sub>, 10.5 &#x003BC;mol/l. In order to clarify the mechanisms behind the inhibition of cell growth, we selected the U87MG cells as the subject for the following experiments (<xref rid="f2-ijmm-32-05-1077" ref-type="fig">Fig. 2</xref>).</p></sec>
<sec>
<title>Cell cycle analysis</title>
<p>After the cells were exposed to various concentrations of saponin B (IC<sub>25</sub>, IC<sub>50</sub> or IC<sub>75</sub>) for 24 h, flow cytometric analysis of the PI-stained cells revealed that substantial numbers of cells accumulated in the S phase of the cell cycle, and that the percentage of cells in the G0/G1 phase decreased, whereas the number of cells in the S and G2/M phases of the cell cycle increased. As shown in <xref rid="f3-ijmm-32-05-1077" ref-type="fig">Fig. 3</xref>, saponin B (IC<sub>75</sub>) significantly increased S phase arrest. These results demonstrate that one mechanism by which saponin B inhibits the growth of U87MG cells is through the induction of S phase cell cycle arrest in a dose-dependent manner (<xref rid="f3-ijmm-32-05-1077" ref-type="fig">Fig. 3</xref>).</p></sec>
<sec>
<title>Cellular and nuclear morphology</title>
<p>Chromatin condensation and nuclear fragmentation, typical of the induction of apoptosis, were observed under a fluorescence microscope using Hoechst 33342 staining. Saponin B induced the characteristic morphological features of apoptosis, including cell shrinkage with condensation of the cytoplasm, membrane blebbing and the formation of apoptotic bodies (<xref rid="f4-ijmm-32-05-1077" ref-type="fig">Fig. 4</xref>). Under a light microscope, with increasing concentrations of saponin B, the cells were increasingly found in rounded form (<xref rid="f4-ijmm-32-05-1077" ref-type="fig">Fig. 4</xref>). Three different types of changes were observed: i) weak and irregularly shaped marginal chromatin condensation; ii) highly condensed nuclear chromatin that was inverted on one side; iii) relatively compact and irregularly shaped marginal chromatin condensation, characteristics of apoptosis (<xref ref-type="bibr" rid="b29-ijmm-32-05-1077">29</xref>,<xref ref-type="bibr" rid="b30-ijmm-32-05-1077">30</xref>).</p></sec>
<sec>
<title>Annexin V-PI dual staining</title>
<p>In the present study, we investigated the effects of saponin B on the apoptosis of U87MG glioblastoma cells. Fluorophore-labeled Annexin V (a protein that exhibits nanomolar affinity for OS) binding to externalized PS has been extensively employed as a reliable marker of apoptosis (<xref ref-type="bibr" rid="b31-ijmm-32-05-1077">31</xref>). To establish whether such processes were induced due to treatment with saponin B, the U87MG cells were exposed to various reagent concentrations (5.2, 6.7 and 8.7 &#x003BC;mol/l) for 8 and 24 h. As shown in <xref rid="f5-ijmm-32-05-1077" ref-type="fig">Fig. 5</xref>, the untreated control cells showed few or no apoptotic cells, whereas apoptosis was markedly induced by saponin B compared with the untreated controls.</p></sec>
<sec>
<title>DNA fragmentation</title>
<p>As shown in <xref rid="f6-ijmm-32-05-1077" ref-type="fig">Fig. 6B</xref>, the untreated control group showed few or no apoptotic cells, whereas apoptosis was markedly induced by saponin B. To further confirm that saponin B induced apoptosis, a DNA fragmentation assay was performed. After the U87MG cells were treated for 24 h with saponin B, cellular DNA revealed a distinctive ladder pattern of DNA cleavage in the apoptotic U87MG cells.</p></sec>
<sec>
<title>Western blot analysis</title>
<p>The Bax, caspase-3 and Fas-l proteins were upregulated in the treated groups following exposure to saponin B, and the expression levels of a typical pro-survival protein (Bcl-2) were downregulated by saponin B (<xref rid="f6-ijmm-32-05-1077" ref-type="fig">Fig. 6A, C and D</xref>). &#x003B2;-actin expression was monitored to ensure that an equal amount of protein was loaded in each lane. Monitoring revealed the expression of pro-apoptotic proteins (caspase-3, Bax and Fas-l) in a dose-dependent manner, and time-dependence was shown by comparison between the 8 and 24 h observations (<xref rid="f6-ijmm-32-05-1077" ref-type="fig">Fig. 6E, G and H</xref>). The decreased expression of Bcl-2 was observed (<xref rid="f6-ijmm-32-05-1077" ref-type="fig">Fig. 6F</xref>).</p></sec></sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>GBM, which is categorized amongst the tumors with the greatest angiogenic ability and occurs more frequently than other types of primary tumors of the central nervous system, is a highly vascularized and invasive malignant tumor with poor clinical outcomes. Even after optimal aggressive surgery, radiation and chemotherapy treatments, the mean reported survival rate is less than one year (<xref ref-type="bibr" rid="b32-ijmm-32-05-1077">32</xref>). Traditional Chinese medicinal herbs are widely known to be effective in the treatment of several diseases. It has been reported that among the 155 small molecular antitumor drugs developed from the 1940s to June 2006, 47&#x00025; are natural compounds or are directly derived from natural compounds (<xref ref-type="bibr" rid="b33-ijmm-32-05-1077">33</xref>); thus, the development of chemopreventive agents derived from Chinese medicinal herbs is an important area of cancer research.</p>
<p>The present study demonstrates the potent and selective cytostatic effects of saponin B in a panel of U87MG GBM cell lines. We demonstrate that saponin B exerts a strong time- and dose-dependent growth inhibitory effect on highly malignant human glioma cell lines, an effect that was confirmed by an MTT assay. The antitumor effects of saponin B may result from multiple mechanisms of action, such as interfering with cell cycle progression and inducing apoptosis.</p>
<p>Mammalian cells have evolved a complex defense network to maintain genomic integrity by inhibiting the fixation of permanent damage. Cell cycle checkpoints prevent cells with damaged genomes from undergoing DNA replication or mitosis (<xref ref-type="bibr" rid="b34-ijmm-32-05-1077">34</xref>). The control of the cell cycle progression in cancer cells is a potentially effective strategy for controling tumor growth (<xref ref-type="bibr" rid="b35-ijmm-32-05-1077">35</xref>). In the study by Zhou <italic>et al,</italic> using flow cytometric analysis of DNA in U87MG cells, the authors demonstrated that novaeguinoside II induced the prominent appearance of an S phase peak in the cell cycle (<xref ref-type="bibr" rid="b36-ijmm-32-05-1077">36</xref>). Therefore, in this study, we analyzed the effects of saponin B on the cell cycle distribution of U87MG glioblastoma cells in order to elucidate the mechanisms behind the inhibition of proliferation. Our data indicated that exposure to saponin B resulted in an increased S phase arrest in the GBM cells, which suggests that DNA synthesis was inhibited by saponin B.</p>
<p>Following exposure to saponin B, apoptotic cells aggregated, shrank and detached from the surface of the culture flask. Hoechst 33342 staining of the nuclei revealed fragmented nuclei in the treated cells. The classical alterations of apoptosis were more distinct in the 24 h-treated group than those of the 8 h-treated group. These results were consistent with the changes observed under a light microscope. This observation confirmed the data obtained by Annexin V/PI assay.</p>
<p>When the U87MG cells were exposed to 5.2, 6.7 and 8.7 &#x003BC;mol/l saponin B for 8 and 24 h, the apoptotic ratio was proportional to the concentration and treatment time. Annexin V/PI assay suggested that PS externalization was apparent at the higher drug concentrations. A significant induction of apoptosis following treatment with saponin B demonstrated its anticancer effects on GBM cell lines. The results were consistent with the biochemical characteristics of apoptosis that PS externalization is an early and sensitive event during the cascade of apoptosis (<xref ref-type="bibr" rid="b37-ijmm-32-05-1077">37</xref>). Taken together, our data demonstrate that the potent effects of saponin B on apoptosis and cell cycle progression indicate that saponin B is able to trigger different signal transduction pathways and to exert effects on two key processes in glioma cells.</p>
<p>Treatment of the GBM cells with saponin B triggered an intrinsic caspase cascade due to an increase in the Bax:Bcl-2 ratio. Bax and Bcl-2 have been reported to play a dominating role in determining whether cells die or survive (<xref ref-type="bibr" rid="b38-ijmm-32-05-1077">38</xref>). The Bcl-2 family members are characterized by containing at least one of four Bcl-2 homology domains (BH1&#x02013;BH4) and play important roles in regulating apoptosis (<xref ref-type="bibr" rid="b39-ijmm-32-05-1077">39</xref>). The increased expression of Bax can induce apoptosis through the release of cytochrome <italic>c</italic> from the mitochondria, while Bcl-2 protects cells from apoptosis through teh stabilization of the mitochondrial membrane potential (<xref ref-type="bibr" rid="b40-ijmm-32-05-1077">40</xref>). As described above, our results suggest that saponin B is a potent compound, exerting apoptotic effects on tumor cells. Several studies have revealed that apoptosis induced by saponin is modulated through a mitochondrial-dependent pathway, which was ascertained in our study by the upregulated Bax protein and downregulated Bcl-2 protein expression.</p>
<p>Furthermore, we employed western blot analysis to elucidate the involvement of the Fas-l protein in saponin B-mediated apoptosis in U87MG cells. It is widely known that the Fas-l/Fas-signaling-mediated death receptor apoptotic pathway is a potential target of antitumor therapy (<xref ref-type="bibr" rid="b41-ijmm-32-05-1077">41</xref>); thus, targeting the death receptor pathway may provide more significant benefits for U87MG GBM cells. Our results testified that the Fas-l/Fas-signaling pathway played a crucial role in saponin B-induced apoptosis. As is also widely known, caspase-3 activation plays a key role in the execution phase of apoptosis and is often preceded by Bcl-2, Bax and caspase-9, via the mitochondrial pathway (<xref ref-type="bibr" rid="b42-ijmm-32-05-1077">42</xref>), and has been identified as being a key mediator of apoptotic events in either cancerous or non-cancerous mammalian cells, such as neuronal cells and GBM cells (<xref ref-type="bibr" rid="b43-ijmm-32-05-1077">43</xref>). Therefore, caspase-3 is ascertained to be a common executive proteolytic enzyme in both the extrinsic and intrinsic apoptotic pathways. In this sudy, we examined the increase in active caspase-3 fragments and caspase-3 activity following treatment with saponin B. Saponin B was most effective in increasing caspase-3 activation and activity after 8 and 24 h of treatment.</p>
<p>Collectively, our data suggest that saponin B exerts a strong time- and dose-dependent apoptotic effect on highly malignant human glioma cell lines, rapidly inducing apoptosis through the activation of both the death receptor-mediated and mitochondrial-mediated proteolytic pathways in U87MG cells. A better understanding of the mechanisms behind the chemotherapeutic activity of saponin B would benefit future animal experiments and clinical studies, thereby increasing the prospects for the clinical treatment of this highly malignant tumor.</p></sec></body>
<back>
<ack>
<title>Acknowledgements</title>
<p>The authors would like to thank Xiaoyan Chen for her excellent technical assistance. This study was supported by grants from the National Natural Science Foundation of China (nos. 30873402 and 81274029) and the Natural Science Foundation of Shaanxi Province (no. 2012JM4010).</p></ack>
<ref-list>
<title>References</title>
<ref id="b1-ijmm-32-05-1077"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeAngelis</surname><given-names>LM</given-names></name></person-group><article-title>Brain tumors</article-title><source>N Engl J Med</source><volume>344</volume><fpage>114</fpage><lpage>123</lpage><year>2001</year></element-citation></ref>
<ref id="b2-ijmm-32-05-1077"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stupp</surname><given-names>R</given-names></name><name><surname>Mason</surname><given-names>WP</given-names></name><name><surname>van den Bent</surname><given-names>MJ</given-names></name><name><surname>Weller</surname><given-names>M</given-names></name><name><surname>Fisher</surname><given-names>B</given-names></name><name><surname>Taphoorn</surname><given-names>MJ</given-names></name><name><surname>Belanger</surname><given-names>K</given-names></name><name><surname>Brandes</surname><given-names>AA</given-names></name><name><surname>Marosi</surname><given-names>C</given-names></name><name><surname>Bogdahn</surname><given-names>U</given-names></name><name><surname>Curschmann</surname><given-names>J</given-names></name><name><surname>Janzer</surname><given-names>RC</given-names></name><name><surname>Ludwin</surname><given-names>SK</given-names></name><name><surname>Gorlia</surname><given-names>T</given-names></name><name><surname>Allgeier</surname><given-names>A</given-names></name><name><surname>Lacombe</surname><given-names>D</given-names></name><name><surname>Cairncross</surname><given-names>JG</given-names></name><name><surname>Eisenhauer</surname><given-names>E</given-names></name><name><surname>Mirimanoff</surname><given-names>RO</given-names></name></person-group><article-title>Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma</article-title><source>N Engl J Med</source><volume>352</volume><fpage>987</fpage><lpage>996</lpage><year>2005</year></element-citation></ref>
<ref id="b3-ijmm-32-05-1077"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ballman</surname><given-names>KV</given-names></name><name><surname>Buckner</surname><given-names>JC</given-names></name><name><surname>Brown</surname><given-names>PD</given-names></name><name><surname>Giannini</surname><given-names>C</given-names></name><name><surname>Flynn</surname><given-names>PJ</given-names></name><name><surname>LaPlant</surname><given-names>BR</given-names></name><name><surname>Jaeckle</surname><given-names>KA</given-names></name></person-group><article-title>The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme</article-title><source>Neuro Oncol</source><volume>9</volume><fpage>29</fpage><lpage>38</lpage><year>2007</year></element-citation></ref>
<ref id="b4-ijmm-32-05-1077"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamborn</surname><given-names>KR</given-names></name><name><surname>Yung</surname><given-names>WK</given-names></name><name><surname>Chang</surname><given-names>SM</given-names></name><name><surname>Wen</surname><given-names>PY</given-names></name><name><surname>Cloughesy</surname><given-names>TF</given-names></name><name><surname>DeAngelis</surname><given-names>LM</given-names></name><name><surname>Robins</surname><given-names>HI</given-names></name><name><surname>Lieberman</surname><given-names>FS</given-names></name><name><surname>Fine</surname><given-names>HA</given-names></name><name><surname>Fink</surname><given-names>KL</given-names></name><name><surname>Junck</surname><given-names>L</given-names></name><name><surname>Abrey</surname><given-names>L</given-names></name><name><surname>Gilbert</surname><given-names>MR</given-names></name><name><surname>Mehta</surname><given-names>M</given-names></name><name><surname>Kuhn</surname><given-names>JG</given-names></name><name><surname>Aldape</surname><given-names>KD</given-names></name><name><surname>Hibberts</surname><given-names>J</given-names></name><name><surname>Peterson</surname><given-names>PM</given-names></name><name><surname>Prados</surname><given-names>MD</given-names></name></person-group><article-title>Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas</article-title><source>Neuro Oncol</source><volume>10</volume><fpage>162</fpage><lpage>170</lpage><year>2008</year></element-citation></ref>
<ref id="b5-ijmm-32-05-1077"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Curtin</surname><given-names>JF</given-names></name><name><surname>King</surname><given-names>GD</given-names></name><name><surname>Candolfi</surname><given-names>M</given-names></name><name><surname>Greeno</surname><given-names>RB</given-names></name><name><surname>Kroeger</surname><given-names>KM</given-names></name><name><surname>Lowenstein</surname><given-names>PR</given-names></name><name><surname>Castro</surname><given-names>MG</given-names></name></person-group><article-title>Combining cytotoxic and immune-mediated gene therapy to treat brain tumors</article-title><source>Curr Top Med Chem</source><volume>5</volume><fpage>1151</fpage><lpage>1170</lpage><year>2005</year></element-citation></ref>
<ref id="b6-ijmm-32-05-1077"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fulda</surname><given-names>S</given-names></name><name><surname>Jeremias</surname><given-names>I</given-names></name><name><surname>Steiner</surname><given-names>HH</given-names></name><name><surname>Pietsch</surname><given-names>T</given-names></name><name><surname>Debatin</surname><given-names>KM</given-names></name></person-group><article-title>Betulinic acid: a new cytotoxic agent against malignant brain-tumor cells</article-title><source>Int J Cancer</source><volume>82</volume><fpage>435</fpage><lpage>441</lpage><year>1999</year></element-citation></ref>
<ref id="b7-ijmm-32-05-1077"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>YS</given-names></name><name><surname>Jin</surname><given-names>DQ</given-names></name><name><surname>Kwon</surname><given-names>EJ</given-names></name><name><surname>Park</surname><given-names>SH</given-names></name><name><surname>Lee</surname><given-names>ES</given-names></name><name><surname>Jeong</surname><given-names>TC</given-names></name><name><surname>Nam</surname><given-names>DH</given-names></name><name><surname>Huh</surname><given-names>K</given-names></name><name><surname>Kim</surname><given-names>JA</given-names></name></person-group><article-title>Asiatic acid, a triterpene, induces apoptosis through intracellular Ca<sup>2&#x0002B;</sup> release and enhanced expression of p53 in HepG2 human hepatoma cells</article-title><source>Cancer Lett</source><volume>186</volume><fpage>83</fpage><lpage>91</lpage><year>2002</year></element-citation></ref>
<ref id="b8-ijmm-32-05-1077"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cragg</surname><given-names>GM</given-names></name><name><surname>Newman</surname><given-names>DJ</given-names></name></person-group><article-title>Plants as a source of anti-cancer agents</article-title><source>J Ethnopharmacol</source><volume>100</volume><fpage>72</fpage><lpage>79</lpage><year>2005</year></element-citation></ref>
<ref id="b9-ijmm-32-05-1077"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gordaliza</surname><given-names>M</given-names></name></person-group><article-title>Natural products as leads to anticancer drugs</article-title><source>Clin Transl Oncol</source><volume>9</volume><fpage>767</fpage><lpage>776</lpage><year>2007</year></element-citation></ref>
<ref id="b10-ijmm-32-05-1077"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>XY</given-names></name><name><surname>Chen</surname><given-names>XL</given-names></name><name><surname>Tang</surname><given-names>HF</given-names></name><name><surname>Gao</surname><given-names>H</given-names></name><name><surname>Tian</surname><given-names>XR</given-names></name><name><surname>Zhang</surname><given-names>PH</given-names></name></person-group><article-title>Cytotoxic triterpenoid saponins from the rhizomes of <italic>Anemone taipaiensis</italic></article-title><source>Planta Med</source><volume>77</volume><fpage>1550</fpage><lpage>1554</lpage><year>2011</year></element-citation></ref>
<ref id="b11-ijmm-32-05-1077"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geske</surname><given-names>FJ</given-names></name><name><surname>Gerschenson</surname><given-names>LE</given-names></name></person-group><article-title>The biology of apoptosis</article-title><source>Hum Pathol</source><volume>32</volume><fpage>1029</fpage><lpage>1038</lpage><year>2001</year></element-citation></ref>
<ref id="b12-ijmm-32-05-1077"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>R</given-names></name><name><surname>Herbert</surname><given-names>PE</given-names></name><name><surname>Warrens</surname><given-names>AN</given-names></name></person-group><article-title>An introduction to death receptors in apoptosis</article-title><source>Int J Surg</source><volume>3</volume><fpage>268</fpage><lpage>277</lpage><year>2005</year></element-citation></ref>
<ref id="b13-ijmm-32-05-1077"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abd-Elrahman</surname><given-names>I</given-names></name><name><surname>Hershko</surname><given-names>K</given-names></name><name><surname>Neuman</surname><given-names>T</given-names></name><name><surname>Nachmias</surname><given-names>B</given-names></name><name><surname>Perlman</surname><given-names>R</given-names></name><name><surname>Ben-Yehuda</surname><given-names>D</given-names></name></person-group><article-title>The inhibitor of apoptosis protein Livin (ML-IAP) plays a dual role in tumorigenicity</article-title><source>Cancer Res</source><volume>69</volume><fpage>5475</fpage><lpage>5480</lpage><year>2009</year></element-citation></ref>
<ref id="b14-ijmm-32-05-1077"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mickisch</surname><given-names>G</given-names></name><name><surname>Fajta</surname><given-names>S</given-names></name><name><surname>Keilhauer</surname><given-names>G</given-names></name><name><surname>Schlick</surname><given-names>E</given-names></name><name><surname>Tschada</surname><given-names>R</given-names></name><name><surname>Alken</surname><given-names>P</given-names></name></person-group><article-title>Chemosensitivity testing of primary human renal cell carcinoma by a tetrazolium based microculture assay (MTT)</article-title><source>Urol Res</source><volume>18</volume><fpage>131</fpage><lpage>136</lpage><year>1990</year></element-citation></ref>
<ref id="b15-ijmm-32-05-1077"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vindelov</surname><given-names>L</given-names></name><name><surname>Christensen</surname><given-names>IJ</given-names></name></person-group><article-title>An integrated set of methods for routine flow cytometric DNA analysis</article-title><source>Methods Cell Biol</source><volume>33</volume><fpage>127</fpage><lpage>137</lpage><year>1990</year></element-citation></ref>
<ref id="b16-ijmm-32-05-1077"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scaife</surname><given-names>RM</given-names></name></person-group><article-title>G2 cell cycle arrest, down-regulation of cyclin B, and induction of mitotic catastrophe by the flavoprotein inhibitor diphenyleneiodonium</article-title><source>Mol Cancer Ther</source><volume>3</volume><fpage>1229</fpage><lpage>1237</lpage><year>2004</year></element-citation></ref>
<ref id="b17-ijmm-32-05-1077"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Handrick</surname><given-names>R</given-names></name><name><surname>Rudner</surname><given-names>J</given-names></name><name><surname>Muller</surname><given-names>I</given-names></name><name><surname>Eibl</surname><given-names>H</given-names></name><name><surname>Belka</surname><given-names>C</given-names></name><name><surname>Jendrossek</surname><given-names>V</given-names></name></person-group><article-title>Bcl-2 mediated inhibition of erucylphosphocholine-induced apoptosis depends on its subcellular localisation</article-title><source>Biochem Pharmacol</source><volume>70</volume><fpage>837</fpage><lpage>850</lpage><year>2005</year></element-citation></ref>
<ref id="b18-ijmm-32-05-1077"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Narayan</surname><given-names>P</given-names></name><name><surname>Mentzer</surname><given-names>RJ</given-names></name><name><surname>Lasley</surname><given-names>RD</given-names></name></person-group><article-title>Annexin V staining during reperfusion detects cardiomyocytes with unique properties</article-title><source>Am J Physiol Heart Circ Physiol</source><volume>281</volume><fpage>H1931</fpage><lpage>H1937</lpage><year>2001</year></element-citation></ref>
<ref id="b19-ijmm-32-05-1077"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huigsloot</surname><given-names>M</given-names></name><name><surname>Tijdens</surname><given-names>IB</given-names></name><name><surname>Mulder</surname><given-names>GJ</given-names></name><name><surname>van de Water</surname><given-names>B</given-names></name></person-group><article-title>Differential regulation of doxorubicin-induced mitochondrial dysfunction and apoptosis by Bcl-2 in mammary adenocarcinoma (MTLn3) cells</article-title><source>J Biol Chem</source><volume>277</volume><fpage>35869</fpage><lpage>35879</lpage><year>2002</year></element-citation></ref>
<ref id="b20-ijmm-32-05-1077"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malerba</surname><given-names>I</given-names></name><name><surname>Gribaldo</surname><given-names>L</given-names></name><name><surname>Diodovich</surname><given-names>C</given-names></name><name><surname>Carloni</surname><given-names>M</given-names></name><name><surname>Meschini</surname><given-names>R</given-names></name><name><surname>Bowe</surname><given-names>G</given-names></name><name><surname>Collotta</surname><given-names>A</given-names></name></person-group><article-title>Induction of apoptosis and inhibition of telomerase activity in human bone marrow and HL-60 p53 null cells treated with anti-cancer drugs</article-title><source>Toxicol In Vitro</source><volume>19</volume><fpage>523</fpage><lpage>532</lpage><year>2005</year></element-citation></ref>
<ref id="b21-ijmm-32-05-1077"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Tang</surname><given-names>HF</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>XH</given-names></name><name><surname>Cao</surname><given-names>WD</given-names></name><name><surname>Gao</surname><given-names>DK</given-names></name><name><surname>Wang</surname><given-names>XL</given-names></name><name><surname>Jin</surname><given-names>BQ</given-names></name></person-group><article-title>Asterosaponin 1, a cytostatic compound from the starfish <italic>Culcita novaeguineae</italic>, functions by inducing apoptosis in human glioblastoma U87MG cells</article-title><source>J Neurooncol</source><volume>79</volume><fpage>235</fpage><lpage>241</lpage><year>2006</year></element-citation></ref>
<ref id="b22-ijmm-32-05-1077"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>XY</given-names></name><name><surname>Hao</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>XY</given-names></name><name><surname>Ba</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Ni</surname><given-names>SJ</given-names></name><name><surname>Wang</surname><given-names>LS</given-names></name><name><surname>Du</surname><given-names>X</given-names></name></person-group><article-title>Licochalcone A inhibits growth of gastric cancer cells by arresting cell cycle progression and inducing apoptosis</article-title><source>Cancer Lett</source><volume>302</volume><fpage>69</fpage><lpage>75</lpage><year>2011</year></element-citation></ref>
<ref id="b23-ijmm-32-05-1077"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ha</surname><given-names>ES</given-names></name><name><surname>Lee</surname><given-names>EO</given-names></name><name><surname>Yoon</surname><given-names>TJ</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Park</surname><given-names>JO</given-names></name><name><surname>Lim</surname><given-names>NC</given-names></name><name><surname>Jung</surname><given-names>SK</given-names></name><name><surname>Yoon</surname><given-names>BS</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name></person-group><article-title>Methylene chloride fraction of <italic>Spatholobi Caulis</italic> induces apoptosis via caspase dependent pathway in U937 cells</article-title><source>Biol Pharm Bull</source><volume>27</volume><fpage>1348</fpage><lpage>1352</lpage><year>2004</year></element-citation></ref>
<ref id="b24-ijmm-32-05-1077"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edinger</surname><given-names>AL</given-names></name><name><surname>Thompson</surname><given-names>CB</given-names></name></person-group><article-title>Death by design: apoptosis, necrosis and autophagy</article-title><source>Curr Opin Cell Biol</source><volume>16</volume><fpage>663</fpage><lpage>669</lpage><year>2004</year></element-citation></ref>
<ref id="b25-ijmm-32-05-1077"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sperandio</surname><given-names>S</given-names></name><name><surname>de Belle</surname><given-names>I</given-names></name><name><surname>Bredesen</surname><given-names>DE</given-names></name></person-group><article-title>An alternative, nonapoptotic form of programmed cell death</article-title><source>Proc Natl Acad Sci USA</source><volume>97</volume><fpage>14376</fpage><lpage>14381</lpage><year>2000</year></element-citation></ref>
<ref id="b26-ijmm-32-05-1077"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhai</surname><given-names>D</given-names></name><name><surname>Jin</surname><given-names>C</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name><name><surname>Satterthwait</surname><given-names>AC</given-names></name><name><surname>Reed</surname><given-names>JC</given-names></name></person-group><article-title>Differential regulation of Bax and Bak by anti-apoptotic Bcl-2 family proteins Bcl-B and Mcl-1</article-title><source>J Biol Chem</source><volume>283</volume><fpage>9580</fpage><lpage>9586</lpage><year>2008</year></element-citation></ref>
<ref id="b27-ijmm-32-05-1077"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rega</surname><given-names>MF</given-names></name><name><surname>Leone</surname><given-names>M</given-names></name><name><surname>Jung</surname><given-names>D</given-names></name><name><surname>Cotton</surname><given-names>NJ</given-names></name><name><surname>Stebbins</surname><given-names>JL</given-names></name><name><surname>Pellecchia</surname><given-names>M</given-names></name></person-group><article-title>Structure-based discovery of a new class of Bcl-xL antagonists</article-title><source>Bioorg Chem</source><volume>35</volume><fpage>344</fpage><lpage>353</lpage><year>2007</year></element-citation></ref>
<ref id="b28-ijmm-32-05-1077"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tse</surname><given-names>C</given-names></name><name><surname>Shoemaker</surname><given-names>AR</given-names></name><name><surname>Adickes</surname><given-names>J</given-names></name><name><surname>Anderson</surname><given-names>MG</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Jin</surname><given-names>S</given-names></name><name><surname>Johnson</surname><given-names>EF</given-names></name><name><surname>Marsh</surname><given-names>KC</given-names></name><name><surname>Mitten</surname><given-names>MJ</given-names></name><name><surname>Nimmer</surname><given-names>P</given-names></name><name><surname>Roberts</surname><given-names>L</given-names></name><name><surname>Tahir</surname><given-names>SK</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Fesik</surname><given-names>S</given-names></name><name><surname>Rosenberg</surname><given-names>SH</given-names></name><name><surname>Elmore</surname><given-names>SW</given-names></name></person-group><article-title>ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor</article-title><source>Cancer Res</source><volume>68</volume><fpage>3421</fpage><lpage>3428</lpage><year>2008</year></element-citation></ref>
<ref id="b29-ijmm-32-05-1077"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leist</surname><given-names>M</given-names></name><name><surname>Jaattela</surname><given-names>M</given-names></name></person-group><article-title>Four deaths and a funeral: from caspases to alternative mechanisms</article-title><source>Nat Rev Mol Cell Biol</source><volume>2</volume><fpage>589</fpage><lpage>598</lpage><year>2001</year></element-citation></ref>
<ref id="b30-ijmm-32-05-1077"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lovborg</surname><given-names>H</given-names></name><name><surname>Nygren</surname><given-names>P</given-names></name><name><surname>Larsson</surname><given-names>R</given-names></name></person-group><article-title>Multiparametric evaluation of apoptosis: effects of standard cytotoxic agents and the cyanoguanidine CHS 828</article-title><source>Mol Cancer Ther</source><volume>3</volume><fpage>521</fpage><lpage>526</lpage><year>2004</year></element-citation></ref>
<ref id="b31-ijmm-32-05-1077"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Narayan</surname><given-names>P</given-names></name><name><surname>Mentzer</surname><given-names>RJ</given-names></name><name><surname>Lasley</surname><given-names>RD</given-names></name></person-group><article-title>Annexin V staining during reperfusion detects cardiomyocytes with unique properties</article-title><source>Am J Physiol Heart Circ Physiol</source><volume>281</volume><fpage>H1931</fpage><lpage>H1937</lpage><year>2001</year></element-citation></ref>
<ref id="b32-ijmm-32-05-1077"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaur</surname><given-names>B</given-names></name><name><surname>Tan</surname><given-names>C</given-names></name><name><surname>Brat</surname><given-names>DJ</given-names></name><name><surname>Post</surname><given-names>DE</given-names></name><name><surname>Van Meir</surname><given-names>EG</given-names></name></person-group><article-title>Genetic and hypoxic regulation of angiogenesis in gliomas</article-title><source>J Neurooncol</source><volume>70</volume><fpage>229</fpage><lpage>243</lpage><year>2004</year></element-citation></ref>
<ref id="b33-ijmm-32-05-1077"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newman</surname><given-names>DJ</given-names></name><name><surname>Cragg</surname><given-names>GM</given-names></name></person-group><article-title>Natural products as sources of new drugs over the last 25 years</article-title><source>J Nat Prod</source><volume>70</volume><fpage>461</fpage><lpage>477</lpage><year>2007</year></element-citation></ref>
<ref id="b34-ijmm-32-05-1077"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shackelford</surname><given-names>RE</given-names></name><name><surname>Kaufmann</surname><given-names>WK</given-names></name><name><surname>Paules</surname><given-names>RS</given-names></name></person-group><article-title>Cell cycle control, checkpoint mechanisms, and genotoxic stress</article-title><source>Environ Health Perspect</source><volume>107</volume><issue>Suppl 1</issue><fpage>5</fpage><lpage>24</lpage><year>1999</year></element-citation></ref>
<ref id="b35-ijmm-32-05-1077"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mork</surname><given-names>CN</given-names></name><name><surname>Faller</surname><given-names>DV</given-names></name><name><surname>Spanjaard</surname><given-names>RA</given-names></name></person-group><article-title>A mechanistic approach to anticancer therapy: targeting the cell cycle with histone deacetylase inhibitors</article-title><source>Curr Pharm Des</source><volume>11</volume><fpage>1091</fpage><lpage>1104</lpage><year>2005</year></element-citation></ref>
<ref id="b36-ijmm-32-05-1077"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>G</given-names></name><name><surname>Cheng</surname><given-names>G</given-names></name><name><surname>Tang</surname><given-names>HF</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name></person-group><article-title>Novaeguinoside II inhibits cell proliferation and induces apoptosis of human brain glioblastoma U87MG cells through the mitochondrial pathway</article-title><source>Brain Res</source><volume>1372</volume><fpage>22</fpage><lpage>28</lpage><year>2011</year></element-citation></ref>
<ref id="b37-ijmm-32-05-1077"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Meng</surname><given-names>XW</given-names></name><name><surname>Flatten</surname><given-names>KS</given-names></name><name><surname>Loegering</surname><given-names>DA</given-names></name><name><surname>Kaufmann</surname><given-names>SH</given-names></name></person-group><article-title>Phosphatidylserine exposure during apoptosis reflects bidirectional trafficking between plasma membrane and cytoplasm</article-title><source>Cell Death Differ</source><volume>20</volume><fpage>64</fpage><lpage>76</lpage><year>2013</year></element-citation></ref>
<ref id="b38-ijmm-32-05-1077"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korsmeyer</surname><given-names>SJ</given-names></name><name><surname>Shutter</surname><given-names>JR</given-names></name><name><surname>Veis</surname><given-names>DJ</given-names></name><name><surname>Merry</surname><given-names>DE</given-names></name><name><surname>Oltvai</surname><given-names>ZN</given-names></name></person-group><article-title>Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death</article-title><source>Semin Cancer Biol</source><volume>4</volume><fpage>327</fpage><lpage>332</lpage><year>1993</year></element-citation></ref>
<ref id="b39-ijmm-32-05-1077"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Juin</surname><given-names>P</given-names></name><name><surname>Geneste</surname><given-names>O</given-names></name><name><surname>Raimbaud</surname><given-names>E</given-names></name><name><surname>Hickman</surname><given-names>JA</given-names></name></person-group><article-title>Shooting at survivors: Bcl-2 family members as drug targets for cancer</article-title><source>Biochim Biophys Acta</source><volume>1644</volume><fpage>251</fpage><lpage>260</lpage><year>2004</year></element-citation></ref>
<ref id="b40-ijmm-32-05-1077"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cory</surname><given-names>S</given-names></name><name><surname>Adams</surname><given-names>JM</given-names></name></person-group><article-title>The Bcl2 family: regulators of the cellular life-or-death switch</article-title><source>Nat Rev Cancer</source><volume>2</volume><fpage>647</fpage><lpage>656</lpage><year>2002</year></element-citation></ref>
<ref id="b41-ijmm-32-05-1077"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ziegler</surname><given-names>DS</given-names></name><name><surname>Kung</surname><given-names>AL</given-names></name></person-group><article-title>Therapeutic targeting of apoptosis pathways in cancer</article-title><source>Curr Opin Oncol</source><volume>20</volume><fpage>97</fpage><lpage>103</lpage><year>2008</year></element-citation></ref>
<ref id="b42-ijmm-32-05-1077"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kleibl</surname><given-names>Z</given-names></name><name><surname>Raisov&#x000E1;</surname><given-names>M</given-names></name><name><surname>Novotn&#x000FD;</surname><given-names>J</given-names></name><name><surname>Pohlreich</surname><given-names>P</given-names></name><name><surname>Matous</surname><given-names>B</given-names></name></person-group><article-title>Apoptosis and its importance in the development and therapy of tumors (review)</article-title><source>Sb Lek</source><volume>103</volume><fpage>1</fpage><lpage>13</lpage><year>2002</year><comment>(In Czech)</comment></element-citation></ref>
<ref id="b43-ijmm-32-05-1077"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sulejczak</surname><given-names>D</given-names></name><name><surname>Grieb</surname><given-names>P</given-names></name><name><surname>Walski</surname><given-names>M</given-names></name><name><surname>Frontczak-Baniewicz</surname><given-names>M</given-names></name></person-group><article-title>Apoptotic death of cortical neurons following surgical brain injury</article-title><source>Folia Neuropathol</source><volume>46</volume><fpage>213</fpage><lpage>219</lpage><year>2008</year></element-citation></ref></ref-list></back>
<floats-group>
<fig id="f1-ijmm-32-05-1077" position="float">
<label>Figure 1</label>
<caption>
<p>(A) Structure of saponin B purified from <italic>Anemone taipaiensis</italic>. (B) The purity of saponin was assessed by high-performance liquid chromatography (HPLC); the chromatographic conditions were as follows: column, YMC-Pack R&amp;D ODS-A (5 mm, 4.6&#x000D7;250 mm I.D.); mobile phase, MeOH:H<sub>2</sub>O (65:35, V/V); flow rate, 1.0 ml/min; temperature, 30&#x000BA;C; detective wavelength, 206 nm.</p></caption>
<graphic xlink:href="IJMM-32-05-1077-g00.gif"/></fig>
<fig id="f2-ijmm-32-05-1077" position="float">
<label>Figure 2</label>
<caption>
<p>Cell viability was determined by MTT assay and the results revealed that saponin B exerted a dose-dependent cytostatic effect on human glioma cells (U87MG and U251MG) at 72 h, which is only approximately 20&#x00025; below the cytotoxic effect on ECV304 human umbilical vein endothelial cells at the highest concentration. The results are shown as the mean values of three experiments &#x000B1; standard deviation (SD). Based on the inhibory concentrations of saponin B &#x0005B;25&#x00025; (IC<sub>25</sub>, 5.2 &#x003BC;mol/l), 50&#x00025; (IC<sub>50</sub>, 6.7 &#x003BC;mol/l) and 75&#x00025; (IC<sub>75</sub>, 8.7 &#x003BC;mol/l)&#x0005D; the U87MG cells were selected to further analyze the effects of saponin B.</p></caption>
<graphic xlink:href="IJMM-32-05-1077-g01.gif"/></fig>
<fig id="f3-ijmm-32-05-1077" position="float">
<label>Figure 3</label>
<caption>
<p>Changes in the cell cycle following treatment with saponin B. (A) Following treatment with various concentrations of saponin B for 24 h, the PI-stained U87MG glioblastoma cells were analyzed by flow cytometry. The data are presented via histograms in which the cell number is plotted against the DNA content. Percentages of cells distributed in the S regions of the histograms are indicated in each histogram. (B) Each value is the mean &#x000B1; SD of three determinations. <sup>&#x0002A;</sup>P&lt;0.05, Dunnett&#x02019;s t-test.</p></caption>
<graphic xlink:href="IJMM-32-05-1077-g02.gif"/></fig>
<fig id="f4-ijmm-32-05-1077" position="float">
<label>Figure 4</label>
<caption>
<p>Determination of residual cell viability and apoptosis in U87MG glioblastoma cells following treatment with saponin B. After the U87MG cells were exposed to various concentrations of saponin B (IC<sub>25</sub>, 5.2 &#x003BC;mol/l; IC<sub>50</sub>, 6.7 &#x003BC;mol/l; and IC<sub>75</sub>, 8.7 &#x003BC;mol/l) for 8 and 24 h, morphological changes were observed under a light microscope. The cells shrank and started to round up in proportion to the increasing concentrations and different time points. The outstanding chromatin condensation and nuclear fragmentation (nuclear condensation, boundary aggregation and split, even DNA fragmentation) for apoptosis induction were visualized under a fluorescence microscope with Hoechst 33342 staining of U87MG cells following treatment with various concentrations of saponin B (IC<sub>25</sub>, IC<sub>50</sub> and IC<sub>75</sub>) for 8 and 24 h.</p></caption>
<graphic xlink:href="IJMM-32-05-1077-g03.gif"/></fig>
<fig id="f5-ijmm-32-05-1077" position="float">
<label>Figure 5</label>
<caption>
<p>(A) Analysis of U87MG cells by flow cytometry demonstrated the transition of cells through an apoptotic phase in response to treatment with saponin B. The U87MG cells were exposed to various reagent concentrations (5.2, 6.7 and 8.7 &#x003BC;mol/l) for 8 and 24 h. Phosphatidylserine (PS) externalization was determined by a combined Annexin V/PI dual staining assay. Necrotic cells are Annexin V<sup>&#x02212;</sup>/PI<sup>&#x0002B;</sup>, healthy cells are Annexin V<sup>&#x02212;</sup>/PI<sup>&#x02212;</sup>, early apoptotic cells are Annexin V<sup>&#x0002B;</sup>/PI<sup>&#x02212;</sup>, and late apoptotic cells are Annexin V<sup>&#x0002B;</sup>/PI<sup>&#x0002B;</sup>. Percentages are displayed in the homologous panel. (B) Effect of saponin B on the apoptosis of U87MG glioblastoma cells at 8 h. <sup>&#x0002A;</sup>P&lt;0.05, Dunnett&#x02019;s t-test. (C) Early and late apoptosis of U87MG cells at 8 h compared with 24 h. <sup>&#x0002A;</sup>P&lt;0.05, paired samples t-test. (D) Effect of saponin B on the apoptosis of U87MG cells at 24 h. <sup>&#x0002A;</sup>P&lt;0.05, Dunnett&#x02019;s t-test.</p></caption>
<graphic xlink:href="IJMM-32-05-1077-g04.gif"/></fig>
<fig id="f6-ijmm-32-05-1077" position="float">
<label>Figure 6</label>
<caption>
<p>(A) Western blot analsyis was used to examine the activation of the intrinsic pathway of apoptosis in U87MG glioblastoma cells. (B) Approximately 1&#x000D7;10<sup>6</sup> U87MG cells were treated and cultured for 24 h with various concentrations of saponin B. Isolated DNA was analyzed using 1&#x00025; agarose gel electrophoresis. (C) After the U87MG cells were treated for 8 h, the ratios for Bax, Bcl-2, caspase-3 and Fas-l were examined at different concentrations. All data are presented as the means &#x000B1; SE of triplicate experiments relative to the control, <sup>&#x0002A;</sup>P&lt;0.05, Dunnett&#x02019;s t-test. (D) After the U87MG cells were treated for 24 h, the ratios for Bax, Bcl-2, caspase-3 and Fas-l were examined at different concentrations. <sup>&#x0002A;</sup>P&lt;0.05, Dunnett&#x02019;s t-test. (E) Bar graph represents the relative expression of the Bax ratio calculated from each group. <sup>&#x0002A;</sup>P&lt;0.05, paired-samples t-test. (F) Bar graph represents the relative expression of the Bcl-2 ratio calculated from each group. <sup>&#x0002A;</sup>P&lt;0.05, paired samples t-test. (G) Bar graph represents the relative expression of the caspase-3 ratio calculated from each group. <sup>&#x0002A;</sup>P&lt;0.05, paired samples t-test. (H) Bar graph represents the relative expression of the Fas-l ratio calculated from each group. <sup>&#x0002A;</sup>P&lt;0.05, paired samples t-test.</p></caption>
<graphic xlink:href="IJMM-32-05-1077-g05.gif"/></fig></floats-group></article>
